Ownership Summary
The institutional landscape for Bone Biologics Corp (NASDAQ:BBLG) includes 7 filers as of the latest reporting cycle ending December 2025.
- The percentage of Bone Biologics owned by institutions changed from 0.7% in September 2025 to 2.8% in December 2025, marking a slight up trend.
- On a quarter-over-quarter basis, institutional holdings shifted by 298.98%, with a year-over-year a decrease of 12.50% in the count of filers.
- A review of institutional activity for Bone Biologics shows 5 of 7 filers increasing their positions, while 0 reduced their stake, and 2 remained unchanged.
- Collectively, institutional investors increased their stake in Bone Biologics to 51.07K shares as of December 2025, a change that is up by 38.27K shares quarter on quarter and down 9.16K shares year over year.
- As of December 31, 2025, DRW Securities, LLC held Bone Biologics's largest shareholding position with over 23.58K shares, representing 1.31% of total outstanding shares.
- Among the most significant buyers of Bone Biologics during December 2025 were DRW Securities, LLC (12.55K), TWO SIGMA INVESTMENTS, LP (11.08K), CITADEL ADVISORS LLC (10.84K), Tower Research Capital LLC (TRC) (1.92K), UBS Group AG (1.88K).
- The top 7 institutional holders of Bone Biologics for the quarter ending December 2025 included DRW Securities, LLC (23.58K), TWO SIGMA INVESTMENTS, LP (11.08K), CITADEL ADVISORS LLC (10.84K), Tower Research Capital LLC (TRC) (3.38K), UBS Group AG (1.95K), SBI Securities Co., Ltd. (230), BANK OF AMERICA CORP /DE/ (14).